820 results found
The NHMRC Corporate Plan 2023–24 presents our strategy for building a healthy Australia, across the strategic themes (purposes) of investment, translation and integrity of health and medical research. The plan also includes our strategic and health priorities, as well as our key activities planned for 2023–24 and over the next four years. The plan describes the operating context in which we work and outlines our performance criteria and targets for the next 4 years. The key elements of our Corporate Plan 2023–24 are summarised in the Plan on a Page.
The National Health and Medical Research Council (NHMRC) Corporate Plan 2022–23 presents our national strategy for health and medical research aligned with our three strategic purposes of investment, translation and integrity. The plan also includes our strategic priorities and health priorities and outlines our key activities planned for 2022–23 and over the next four years. In addition, the plan describes the operating context in which we work and our performance criteria and targets for the next four years
The NHMRC Corporate Plan 2021–22 presents our national strategy for health and medical research aligned with our three strategic purposes of investment, translation and integrity. The plan includes updated strategic priorities and health priorities and outlines our planned key activities in 2021–22 and over the next four years. The plan also describes the operating context in which we work and our performance criteria and targets for the next four years.
The rescinded National Statement on Ethical Conduct in Human Research (2007) (National Statement (2007), and as updated, consists of a series of guidelines made in accordance with the National Health and Medical Research Council Act 1992.
This information kit is divided into 5 chapters, covering different aspects of the NHMRC Embryo Research Licensing Committee’s activities.
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2023–24.An accessible version of this document is available on the Transparency Portal.
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2022–23. An accessible version of this document is available on the Transparency Portal.
Selecting studies and data extraction Ensuring the right articles are included in your evidence review
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2021–22. An accessible version of this document is available on the Transparency Portal.
This document clarifies the responsibilities of those involved in clinical trials to monitor and report adverse events and other safety issues. Supplementary guidance on other clinical trial safety monitoring and reporting issues is also available*.
There are concerns about the increasing availability of health-related genetic testing kits. This guide is for health professionals whose patients are considering buying a test kit or want to discuss their results.
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2019–20. An accessible version of this document is available on the Transparency Portal.
Despite the use of lead being reduced in many industries, it is still found in many environments and is known to have adverse effects on human health. This report evaluates the evidence relating to individual level lead exposure in Australia, the effects from this and the effectiveness of intervention strategies.